IgA Nephropathy: Pathogenesis, the Role of APRIL & the 4-Hit Process, & a Patient Case Study
The goal of this event is to provide a detailed overview of the Four-Hit hypothesis as well as explain the role of APRIL in disease pathogenesis.
- About
- IgAN
- Events
- Resource Center
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Attend live and virtual events that provide a platform for education and collaborative discussion about the management of kidney disease and strategies to improve kidney health.
Any NephU member can request a presentation for their region or organization at no charge.
Featured Events
Events
4 Part IgAN Experience
During this presentation you will learn the clinical presentation, diagnosis, prognosis, and unmet treatment needs of IgAN.
Navigating the Differential Diagnosis of Proteinuria with an Emphasis on IgA Nephropathy
This webinar will focus on the current biomarker landscape as well as novel biomarkers that are currently being studied. The webinar will also focus on why biomarkers are needed and what the unmet need is.
KDIGO Clinical Practice Guideline for the Evaluation, Management, & Treatment of ADPKD (Part 1)
The goal of this webinar series is to review the 2025 KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD.
KDIGO Clinical Practice Guideline for the Evaluation, Management, & Treatment of ADPKD (Part 2)
The goal of this webinar series is to review the 2025 KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD.
KDIGO Clinical Practice Guideline for the Evaluation, Management, & Treatment of ADPKD (Part 3)
The goal of this webinar series is to review the 2025 KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD.
Biomarkers in IgA Nephropathy
This webinar will focus on the current biomarker landscape as well as novel biomarkers that are currently being studied. The webinar will also focus on why biomarkers are needed and what the unmet need is.
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the kidney health community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2025 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - IgAN
